Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › RLMD

Relmada Therapeutics

RLMD Rare disease Lead: Phase 2 2 Biotech Distilled articles ↓ 20 filings & releases ↓ Cash $11.3M (Jun 30, 2026) ↓ 2 verdicts ↓ 2 timing quotes ↓
MetabolicNeurologyOncology Small Molecule

Market cap $416M 106.7M shares (10-Q, Aug 4, 2026) × $3.90 close Nov 6, 2026

Most recent annual filing: 2026-03-19

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. NDV-01 readout2026NDV-01 readout, 2026, material
  2. NDV-01 IND filingyear-end 2026NDV-01 IND filing, year-end 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (2)

Capital (as filed)

Cash
$11.3M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$206M Jun 30, 2026
Operating cash flow
−$9.6M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$218M cash per the update of Aug 6, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Relmada Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-06-23 Watch Relmada Therapeutics (RLMD) — Scientific Deep Dive for NDV-01 and Sepranolone NDV-01 has de-risked biology and a genuine office-based delivery advantage, but pivotal-population data does not yet exist, the edge over approved INLEXZO is convenience rather than proven efficacy, and the team's late-stage track record is poor; the year-end 2026 Cohort 2A readout is the gate to a potential upgrade.
  2. 2026-08-07 Watch UPDATE: Relmada Therapeutics (RLMD) - The Catalyst Just Moved Right Phase 3 initiation slipped from mid-2026 to upon IND clearance due to CMC manufacturing delays, funding language softened, and no efficacy readout is expected in the next twelve months; Watch List maintained with clock reset as the next event is an IND filing, not data.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (20)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 28, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)